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Background:We evaluated the cross-sectional and longitu-
dinal association of measures of both insight and attitudes
toward medication to outcomes that included psychopa-
thology and community functioning.Methods:Clinical An-
tipsychotic Trial of Intervention Effectiveness (CATIE)
was a large 18-month follow-up study pharmacotherapy
of people with schizophrenia. Insight was measured using
the Insight and Treatment Attitudes Questionnaire and
attitudes toward medication by the Drug Attitude Inven-
tory. Widely known scales were used to assess symptoms
of schizophrenia and depression and community function-
ing. Medication adherence was globally assessed by the
treating psychiatrist using several sources of information.
Bivariate correlations and mixedmodel regression analyses
were used to test the relationship of insight and medication
attitudes to outcomes at baseline and during the follow-up
period. Regression models were used to evaluate the rela-
tionship between change in insight and medication attitudes
and changes outcomes. Results: There was a significant re-
lationship at baseline between insight and drug attitudes
and symptoms of schizophrenia and depression, as well
as with community functioning. Higher levels of insight
at baseline were significantly associated with lower levels
of schizophrenia symptoms at follow-up while more positive
medication attitudes were significantly associated with
both lower symptom levels and better community function-
ing. Change in insight scores over time was associated with
declining schizophrenia symptoms but increasing levels of
depression. Change toward more positive medication atti-
tudes was associated, independently of changes in insight,
with significant decreases in psychopathology, improve-
ment in community functioning, and greatermedication com-
pliance. Conclusion: Greater patient understanding of their
illness and more positive attitudes toward medication may
improve outcomes. Educational interventions that affect
these attitudes may be an important part of psychosocial
rehabilitation and/or recovery-oriented services.
Key words: schizophrenia/insight/medication attitude/
social functioning/quality of life
Introduction
Poor insight and denial of illness are prevalent features of
schizophrenia1,2 that are widely believed to have adverse
clinical effects.3 When individuals with schizophrenia do
not perceive themselves as ill, they are less inclined to en-
ter or remain in treatment, underappreciate the benefits
of medication, and put themselves at higher risk of dis-
continuing treatments, with concomitant increase in the
risk of relapse.4 Poor insight into illness and negative atti-
tudes toward medications may thus be important deter-
minants of clinical outcome and may offer useful avenues
for intervention.
Psychopharmacological and psychological treatments
have both been found to significantly decrease symptoms
in schizophrenia and improve functional capacity.5,6 The
long-term course of the illness is nevertheless often char-
acterized by impaired social and occupational function-
ing and quality of life (QOL)7–9 in part because in the
absence of insight and positive attitudes toward available
treatments the chances of realizing their benefits are limited.
In recent years, increasing emphasis has been put on
the importance for people with schizophrenia of having
a ‘‘recovery orientation’’ toward their lives, ie, an orien-
tation characterized by realistic hopefulness and feeling
of empowerment to achieve personal goals in spite of ad-
versity.10–15 Although the recovery orientation among
people with serious mental illness is often contrasted
with a medical model orientation, insight into illness
may represent an important link between the 2 perspec-
tives because people who understand their illness and rec-
ognize the value of available treatments are likely to feel
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more empowered and to bemore successful at using treat-
ment to achieve their personal goals. Acknowledgement
of illness has been recognized as improving the capacity
to make informed decisions about the future to free one-
self from blame for difficulties linked with illness and to
form sustaining bonds with others.16
Although it is impossible to randomly assign patients
to different attitudinal states, observational methods can
be used to evaluate the relationship between insight and
attitudes toward medication and key outcomes such as
schizophrenia symptoms, depression, social functioning,
as well as medication compliance. Particular attention
must be given in such studies to alternative explanations
for the associations of insight and medication attitudes
such as reverse causality and bidirectionality, and statis-
tical adjustments should be used to reduce potential
biases. By linking consumer attitudes and knowledge
to use of treatment, and desirable outcomes, this line
of research may provide an integrative link between
the recovery and medical models.
Although researchers agree that there are multiple
components of insight, there is empirical evidence sug-
gesting that these dimensions actually represent compo-
nents of a single construct. McEvoy et al17 administered
a standardized interview that assessed awareness of ill-
ness, need for treatment, and understanding the conse-
quences of the disorder. A principal components analysis
of these data resulted in a single-factor solution. A similar
study involving a self-report measure that assessed aware-
ness of illness, need for treatment, and recognition of the
relationship of symptoms to the disorder18 also obtained
a single-factor solution in a principal components analysis.
Most recently, Cuesta et al19 administered 3 separate in-
sight instruments to a group of psychotic patients and
found a 2-factor solution (‘‘general awareness’’ and ‘‘atti-
tudes to treatment’’). However, the first factor accounted
for a much larger percentage of variance than the second
(76.9% vs 9.4%), and the 2 dimensions were highly corre-
lated, further suggesting that these dimensions are best
viewed as multiple, correlated indices of a single construct.
Relationship of Insight to Psychopathology
Cross-sectional studies have found small but significant
relationships20 showing that greater insight is associated
with lower levels of global psychopathology and of both
positive and negative symptoms, including one study that
examined these cross-sectional associations at 2 different
time points.21,22 Investigations that examined whether
changes in insight are associated with changes in symp-
toms have reported less consistent results.17,20,21,23–25 To
our knowledge, no study has simultaneously investigated
the predictive relationship of both insight andmedication
attitudes to outcomes by analyzing the relationship be-
tween these variables at baseline to outcomes at subse-
quent time points, nor has any study addressed the full
range of pertinent outcomes including symptom severity,
depression, QOL, and medication adherence, while con-
trolling for potential baseline confounders.
Insight and Medication Adherence
Cross-sectional studies of the relationship between in-
sight and adherence to treatment have reported that in-
creased insight was associated with greater treatment
adherence.26–33 However, studies that examined the pre-
dictive power of insight and future treatment adherence
have yielded mixed results with some studies finding no
association27,33,34 while one smaller study reported only
a positive trend.35 We are not aware of any studies that
investigated the association between change in insight
and change in medication adherence over time.
Insight and Functional Outcome
Some cross-sectional studies have reported significant
associations between insight and functional out-
comes,24,31,36,37 while others have not.38–42 Most longitu-
dinal studies, in contrast, have reported significant
predictive associations between insight and function-
ing.43–47 However, most of these studies did not control
for symptom severity at baseline and did not examine
the association between change in insight and change in
functioning.
In view of these complex and inconsistent findings, we
sought to examine the strength of association of measures
of both insight and attitudes toward medication to
a broad array of outcomemeasures including schizophre-
nia and depressive symptoms, community functioning,
and treatment adherence. We hypothesized that insight
and medication attitudes would (a) be significantly asso-
ciated with reduced psychopathology and better func-
tional capacity in a cross-sectional analysis using
baseline data and (b) predict net of baseline level of
insight and medication attitude and other potentially
confounding baseline factors (depression, age, QOL, psy-
chopathology, and neurocognition), less future psycho-
pathology, and better social/occupational functioning
and treatment adherence at follow-up. (c) We further
hypothesized that change in insight and medication atti-
tudes from baseline to follow-up would also be signifi-
cantly related to change in clinical measures, after
controlling for potentially confounding factors.
Methods
Study Design
This study used data from the Clinical Antipsychotic Tri-
al of Intervention Effectiveness (CATIE) schizophrenia
study, a large, 18-month, National Institute of Mental
Health–funded, randomized controlled trial designed
Insight in Schizophrenia
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to compare outcomes of 1 conventional antipsychotic
medication (perphenazine) and 4 second-generation anti-
psychotics (olanzapine, ripseridone, quetiapine, and
ziprasidone).48 CATIE was conducted between January
2001 and December 2004 at 57 US sites. The CATIE
study was designed to compare the effectiveness and
cost-effectiveness of currently available atypical and con-
ventional antipsychotic medications through a random-
ized clinical trial involving a large sample of patients
treated for schizophrenia at 57 sites, including both aca-
demic and community providers. Data were included
from all the phases of CATIE.49 Patients were 18–65
years of age who had received a diagnosis of schizophre-
nia, as determined with the Structured Clinical Interview
forDiagnostic and StatisticalManual ofMental Disorders
(Fourth Edition) Axis I Disorders (SCID),50 and who
were able to take oral antipsychotic medication as deter-
mined by the study doctor. Patients were excluded if they
had a diagnosis of schizoaffective disorder, mental retar-
dation, or other cognitive disorders; had a history of se-
rious adverse reactions to the proposed treatments; had
had only one schizophrenic episode; had a history of
treatment resistance; were pregnant or were breast-feed-
ing; or had a serious and unstable medical condition. A
wide spectrum of patients with schizophrenia enrolled in
the study, ranging from partially remitted outpatients
who remain symptomatic (because of lack of efficacy
or inability to tolerate an efficacious dose) or who suffer
significant side effects to exacerbated inpatients. Patients
who are seemingly doing well on their current medication
but who wish to consider a change for reasons of greater
improvement or better tolerability were also welcome to
enroll.
Participants gave written informed consent to partici-
pate in protocols approved by local institutional review
boards. Details of the study design and entry criteria have
been presented elsewhere.49 The diagnosis of schizophre-
nia was confirmed by the SCID. This study relies on base-
line data and follow-up assessments at time points at
which data on symptoms, insight, medication attitude,
and social/vocational functioning were all available (1,
3, 6, 9, 12, 15 and 18 months).
In addition to medications, all participants were of-
fered an individually tailored educational plan adapted
from the successfully implemented Texas Medication Al-
gorithm Project. The plan was conducted in several
phases and invited family participation if desired by
the patient. Contents of the various phases included ed-
ucation on diagnosis, medications, symptom self-
monitoring, side effects, and change in symptoms.
Measures
Insight and Drug Attitudes. Insight was assessed by the
Insight and Treatment Attitudes Questionnaire
(ITAQ).17 The ITAQ was designed to measure awareness
of illness and insight into need for treatment in patients
with schizophrenia. It is a single scale consisting of 11
items that are phrased as questions to elicit responses
on Likert-type scales. Attitudes toward medication
were assessed by the Drug Attitude Inventory (DAI).51
The DAI is widely used, brief, and frequently self-admin-
istered but in the CATIE trial was read to the patient and
true and false responses obtained. The instrument focuses
on unpleasant and negative subjective responses that are
common adverse effects of antipsychotic medications. A
higher score reflects more negative attitudes toward med-
ications. In this study, the scale was reverse scored to re-
flect positive attitudes toward medications so as to
maintain the same directionality as the insight scale.
Schizophrenia and Depressive Psychopathology. Symp-
toms of schizophrenia were assessed by the Positive
andNegative Syndrome Scale (PANSS)52 that yields a to-
tal average symptom score, based on 30 items rated from
1–7 (with higher scores indicating more severe symp-
toms), as well as subscales reflecting positive, negative,
and general psychiatric symptoms. In order to avoid sta-
tistical redundancy between the PANSS measure of gen-
eral psychiatric symptoms and the ITAQ, the PANSS
general and total subscales were modified to exclude
an item that assesses insight. Co-occurring depressive
symptomatology was assessed using the Calgary Depres-
sion Rating Scale (CDRS).53,54 CDRS is a 9-item scale
designed to assess severity of depressive symptoms in
patients with schizophrenia. The CDRS has been shown
to be a reliable and valid measure of depression in this
population.53
Quality of Life. Psychosocial functioning and QOL
were assessed using the Heinrichs-Carpenter Quality of
Life (HQOL)8 Scale and a single item from the Lehman
Quality of Life Interview (LQOLI)83. The HQOL is
a rater-administered scale that assesses overall QOL
and functioning on 21 items rated from 0 to 6 (with higher
scores reflecting better QOL) and yields measures on 4
subscales that address (a) interpersonal relations, (b) in-
strumental role functioning, (c) use of common objects
and participation in activities, and (d) intrapsychic foun-
dation (ie, sense of purpose, motivation, curiosity, and
ability to experience pleasure). This scale has showed
high sensitivity to both change and treatment effect,
and moderate-high correlations with other measures of
QOL.55 The LQOLI is a structured self-report interview
designed to generate ratings by a trained nonclinical in-
terviewer. The single item from the LQOLI asks the pa-
tient to rate his well-being overall on a scale from
terrible = 1 to delighted = 7.
Medication Adherence. Medication adherence was eval-
uated using monthly pill counts. Additionally, information
from patients on structured questions about medication
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adherence were asked at each appointment, along with in-
formation from clinicians and family documenting whether
there had been prescriptionmedications or shots formental
or emotional health problems that the patient was sup-
posed to take but either did not take at all or took only
some of the time were also obtained. A global judgment
on a 1–4 scale with higher scores representing poorer ad-
herence (representing 75%–100% compliance to 0%–25%
compliance) was made by the treating psychiatrist based
on synthesizing all available information including pill
count data.56 While each method of measuring medication
adherence is imperfect,multiplemethods improve estimates
of adherence considerably.84 For the analyses reported
here, we reverse coded this scale to represent increasedmed-
ication adherence.
Side Effects. The Barnes Akasthisia Scale (BAS)57 was
used to evaluate akasthisia. BAS contains 4 items, includ-
ing objective akasthisia, subjective awareness of restless-
ness, subjective distress related to restlessness, and
a global clinical assessment of akasthisia. We assessed
the Abnormal Involuntary Movement Scale (AIMS)
(Guy 1976) to rate symptoms of tardive dyskinesia.
The AIMS has 12 items that rate severity of dyskinetic
movements in various body parts and an overall severity
item, on a scale ranging from 0 to 4. Extrapyramidal
symptomswere assessed using the Simpson-Angus Extra-
pyramidal Side Effect Scale,59 a scale that contains 10
items rated on a scale of 0–4.
Neurocognitive Functioning. Neurocognitive function-
ing was measured by separate test scores, described in
previous publications,60 that were converted to z scores
and combined to construct 5 scales: Processing Speed,
Verbal Memory, Vigilance, Reasoning, and Working
Memory. The Neurocognitive Composite Score was
the average of standardized scores (z scores) of these 5
subscale summary scores.
Analyses
First, Pearson product-moment correlations were used to
evaluate the baseline bivariate associations between in-
sight and medication attitudes, sociodemographic varia-
bles (age, education, and marital status), neurocognition,
symptoms severity, depressive symptoms, functional sta-
tus, and side effects. These correlations identified the
baseline association of attitudinal measures and outcome
measures as well as other variables that were significantly
associated with insight and drug attitudes and that could
thus potentially confound observed relationships be-
tween insight and attitudes and outcomes in longitudinal
mixed models.
The purpose of the primary analyses was to evaluate
the independent associations of insight and medication
attitudes at baseline with subsequent outcome. Primary
analyses were a series of mixed model regressions analy-
ses of outcomes at all time points on the PANSS total
score and subscales, the HQOL total score and subscales,
CDRS, and medication adherence measures. Because
these analyses include multiple observations from the
same patients at different time points, random effects
were modeled to adjust the SEs for the correlation of
observations within individual patients along with fixed
effects representing the time of each assessment (range 1–
18 months). In these models, insight and attitudes toward
medication at baseline were the independent variables of
primary interest. The baseline value of each dependent
variable as well as age, the baseline values of the LQOLI
measure, neurocognition, depression, and the HQOL to-
tal scores were also included as covariates because they
were significantly associated with the baseline measures
of either insight or attitudes toward medication along
with the month of the follow-up assessment.
Because insight was significantly related to some out-
comes while medication attitude, when included in the
same model, was not and reciprocally medication attitude
was significantly related to other outcomes while insight
was not, these analyses were repeated to include baseline
insight or medication attitude each by itself, in separate
models. These analyses were designed to identify cases in
which the significant relationship of one of these variables
to outcomes was not independent of the other measure.
Finally, to examine the longitudinal association be-
tween change in both insight and medication attitude
and the change in symptomatology and HQOL (the as-
sociation between change and change), we constructed an
additional set of measures in which the baseline score on
each measure for each subject was subtracted from each
of their follow-up scores on the outcomes of interest as
well as on the ITAQ and the DAI. The final set of regres-
sion models was used to test the associations between
these measures of change, again using mixed models be-
cause multiple observations were included from each pa-
tient and controlling for potentially confounding baseline
measures as described above including the baseline values
of measures of insight and medication attitudes.
Because previous publications have demonstrated that
there were few significant differences between treatments
in CATIE on the QOLS,61 neurocognitive functioning,62
and symptoms,63 we evaluated whether there were differ-
ences between treatments at follow-up on insight and
medication attitudes. Because we found no significant
differences in outcomes on these measures, treatment
group was not included in any subsequent analysis.
Results
Sample Characteristics
Subjects were 1432 individuals with aDiagnostic and Sta-
tistical Manual of Mental Disorders (Fourth Edition)
diagnosis of schizophrenia validated by the SCID treated
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at 57 US sites (table 1). Patients were middle aged on av-
erage (mean age = 40.5 6 11.1 years), mostly Caucasian
(60.3%), chronic patients with a mean duration of illness
of 16.5 þ 11 years (table 1). As shown previously, the
CATIE sample was similar in sociodemographic and clin-
ical characteristics to participants in other major trials of
atypical antipsychotics.63
Bivariate Analyses
Bivariate correlation analyses showed that the ITAQ and
DAI were significantly positively correlated (r = 0.32,
P < .0001). Correlations between these measures and
other baseline measures showed significant relationships
between both measures and age, lower PANSS scores,
and higher HQOL scores. The relationship of insight
and medication attitudes and depressive symptoms, neu-
rocognitive performance, and the QOLLQOL ran in op-
posite directions such that more insight was correlated
with better performance on cognitive measures, more de-
pressive symptoms, and lower QOLLQOL scores, while
more positive medication attitudes was associated with
associations in the opposite directions on these measures.
A significant relationship was observed between insight
Table 1. Sample Characteristics
N (%) Mean 6 SD Range
Demographic
Age (y) 40.52 6 11.09 18.00–67.00
Male (%) 1099 (74.0)
Race/ethnicity (%)
White 863 (60.3)








Never married 860 (59.44)
Education (years) 12.10 6 2.25 1–21
Clinical
Positive and Negative Syndrome Scale (PANSS)
Positive syndrome scale 18.47 6 5.64 7–49
Negative syndrome scale 20.15 6 6.40 7–40
General PANSS subscalea (no insight) 34.14 6 8.82 16–112
Totala (no insight) 72.76 6 16.97 30–210
Calgary Depression Rating Scale 1.57 6 0.56 0–3
Medication Adherence at follow-up 1.19 6 0.57 1–4
Side effects
Akathisia (Barnes Akathisia Scale) 0.35 6 0.55 0–5
Tardive dyskinesia (Simpson Angus Scale) 0.22 6 0.32 0–4
Extrapyramidal symptoms (Abnormal Involuntary
Movement Scale)
0.26 6 0.46 0–4
Insight
Insight and Treatment Attitudes Questionnaire 0.04 6 0.81 0–2
Drug Attitude Inventory 0.07 6 0.50 0–10
SF 12 Survey Physical health 48.20 6 10.18 0–100
SF 12 Survey Mental health 40.95 6 11.63 1–100
Neurocognitive Composite Score 0.02 6 0.62 2.7–1.7
Functional outcome
Lehman Quality of Life 4.33 6 1.40 0–6
Heinrichs-Carpenter Quality of Life Scale
Interpersonal relations and social 2.53 6 1.30 0–6
Instrumental role functioning 2.00 6 1.65 0–6
Intrapsychic foundations 2.98 6 1.15 0–6
Common Objects and Activities 3.23 6 1.35 0–6
Total 2.74 6 1.06 0–6
Note: SF, 12-Item Short-Form Health Survey.
aPANSS General and Total subscales were modified to exclude an item that assesses insight.
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and being currently or formerlymarried, but no such rela-
tionships were found with medication attitudes (table 2).
Longitudinal Analysis of Outcomes
All outcome measures showed significant improvement
over the 18 months of the study (all P’s < .0001). Higher
levels of insight at baseline were significantly and inde-
pendently associated with lower levels of schizophrenia
symptoms at follow-up (including the PANSS total score
as well as the positive and negative subscales) (table 3)
after adjusting for potentially confounding baseline
measures and for the time of each follow-up assessment.
Insight was also associated with higher scores on the
HQOL intrapsychic foundation score but not on the total
or other subscales orwithmedication compliance (table 3).
A more positive attitude toward medication was also
associated, independently of the insightmeasure, with sig-
nificantly lower levels of symptoms on the total PANSS
score as well as with lower levels of positive symptoms,
general psychopathology, and depression (table 3). Pos-
itive attitudes toward medication were associated with
higher scores onHQOL intrapsychic foundation subscale
score and the measure of medication compliance.
Three outcome measures were significantly associated
with baseline insight, only when drug attitudes were not
included in the model: the HQOL total score (B = 0.069,
t = 2.32, df = 1, 1325, P< .05), the HQOL social relations
score (B = 0.081, t = 2.28, df = 1, 1092, P< .05), and med-
ication adherence (B = .043, t = 2.48, df = 1, 1325, P< .05).
Although these outcome measures were significantly as-
sociated with baseline insight, the relationships were not
independent of positive attitudes toward medications.
Association Between Change in Insight, Medication
Attitude, and Change in Outcome Measures
The final set of analyses showed that change in insight
scores from baseline to follow-up was associated with de-
creased PANSS total scores, as well as positive, negative,
and general symptoms scores; improvement in theHQOL
total and all 4 subscales; and increased medication com-
pliance, as well as with increased levels of depression
(table 3). These analyses all adjusted for the baseline
value of the dependent variable as well as for the potential
confounding baseline measures previously identified and
the time of each follow-up interview.
Change toward more positive medication attitudes, in
these analyses, was associated, independently of changes
in insight, with significant decreases in the PANSS total
score, as well as in the positive, negative, and general
symptom scores, and with decreased levels of depression.
Change toward more positive attitudes toward medica-
tion was also associated with greater improvement in
the HQOL total score, all 4 HQOL subscale scores, as
well as improved medication compliance.
Discussion
This study used a large, longitudinal dataset to examine
the relationship of both awareness of illness and attitudes
toward medication with severity of schizophrenia and
depressive symptoms, social functioning, andmedication
adherence (N = 1432). We found consistent relation-
ships between both insight and attitudes toward med-
ication and clinical outcomes, QOL, and medication
adherence, albeit of varying strength and independence
across analyses.
At baseline, greater insight and more positive attitudes
toward medication were clearly associated with lower lev-
els of schizophrenia symptoms, and higher HQOL scores,
findings similar to those reported in other studies.21,22
Greater insight was correlated not only with better perfor-
mance on cognitive measures, as reported previously,64
but also with more severe depressive symptoms.65,66 Pre-
vious cross-sectional investigations have also reported
weak but positive associations between insight and de-
pressive symptoms (ie, depressive symptoms and insight
increased in parallel)22,47 as well as with increased suicidal
ideation or behaviors.45,67 Poor insight into illness has
been viewed, traditionally, as serving a defensive function
that preserves self-esteem and allows maintenance of an
optimistic outlook in face of the discrepancy between
one’s and others’ functioning or between current and de-
sired functioning. Insight has in fact been considered by
some to be responsible for postpsychotic depression.68










insight) NC Depression AIMS BAS
SAEPS
ES
ITAQ 0.07** 0.04 0.084** 0.084** 0.07** 0.20*** 0.18*** 0.06* 0.12*** 0.01 0.01 0.02
DAI 0.17*** 0.03 0.011 0.047 0.15*** 0.19*** 0.21*** 0.07* 0.12*** 0.04 0.05 0.05
Note: LQOLI, Lehman Quality of Life Interview; HQOL, Heinrichs-Carpenter Quality of Life; PANSS, Positive and Negative
Syndrome Scale; AIMS, Abnormal Involuntary Movement Scale; BAS, Barnes Akathisia Rating Scale; SAEPS, Simpson-Angus
Extrapyramidal Side Effect Scale; ITAQ, Insight and Treatment Attitudes Questionnaire; DAI, Drug Attitude Inventory.
*P < 0.05, **P < 0.01, ***P < 0.001.
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But the causal direction of these cross-sectional baseline
associations, however, is ambiguous, and this relation-
ship could also, as consistent with cognitive models, re-
flect depressive realism (ie, a higher levels of depression
reflecting more accurate self-evaluations of current func-
tioning, commonly found in depression, resulting in
a higher levels of insight into the presence and the impact
of a mental disorder.69
In the longitudinal analyses, we found consistent rela-
tionships between both insight and medication attitudes
at baseline and lower symptoms and higher intrapsychic
functioning at follow-up. Independent relationships with
medication adherence and overall QOL (as well as with
greater depressive symptoms) were only found with base-
line medication attitudes and not with insight. However,
when insight was examined without medication attitudes
in the models, significant relationships were also ob-
served between insight and both medication adherence
and overall QOL, suggesting substantial shared variation
between the 2 independent variables, perhaps explaining
the findings of studies that failed to find a significant re-
lationship between insight and future treatment adher-
ence.27,33,34 In contrast to insight, more positive
attitudes toward medication was associated with lower
levels of depressive symptoms, perhaps mediated by
the more consistent use of effective drugs, primarily anti-
psychotics that have been found to be associated with re-
duced depressive symptoms70,71 and concomitant
medications such as antidepressants.
These longitudinal findings are consistent with and
more suggestive of a causal relationship than cross-
sectional analyses and suggest a potential value for inter-
ventions that improve patients’ awareness of both the
nature of their illness and the potential benefits of
medications.
To examine the mediating effect of medication adher-
ence on the relationship between both insight and med-
ication attitudes and symptoms, we repeated the mixed
regression models adding the measure of medication ad-
herence as a covariate. While the strength of association
between both insight and medication attitudes and symp-
toms (as measured by the size of the regression coeffi-
cients) decreased slightly, they all remained significant.
Thus, greater mediation adherence only partially
accounted for the observed association of insight and
medication attitudes with lower symptoms. Analyses of
the associations between ‘‘change and change’’ were
highly consistent showing significant and independent
relationships between change in both insight and medica-
tion attitudes and change in measures of, symptoms,
QOL, and with medication adherence. The significant
relationships with symptom change are strongly consis-
tent with findings of several earlier symptom stud-
ies.20,23,24,72 However, this is the first study to
demonstrate significant associations between change in
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as with greater medication adherence. The association
between increased insight and decreased symptoms of
schizophrenia and improved community functioning,
in this large well-characterized sample, while not conclu-
sive, adds further support for the possibility of a causal
relationship between insight and outcomes.
Taken together, the results suggest that increasing pa-
tient insight into their illness and fostering positive atti-
tudes toward medication may result in improved
symptom andQOL outcomes. They suggest possible ben-
efits of exploring negative attitudes toward medication in
a client-centered manner. Such an approach should be
based on the development of a supportive therapeutic al-
liance and a strong positive practitioner-consumer rela-
tionship. The nature of this relationship has undergone
major developments in recent years shifting from a hier-
archical medical model to a recovery-oriented model that
requires new ways of understanding and approaching the
issue of medication choice. Deegan and Drake73 sug-
gested that not taking medication as prescribed is
more likely to occur when the medication is perceived
to interfere with highly valued social or occupational ac-
tivities. From this perspective, addressing patients ratio-
nale for not adhering to their medication regimen and
personal problems perceived to be related to medication
may improve adherence and outcomes. However, more
research is needed to better understand how decisions
to take medication are made and how such decisions
can be influenced. For example, one approach to improv-
ing medication adherence involves the use of techniques
designed to instill motivation by exploring the relevance
of taking medication to achieving personal goals.74,75
Pharmacologically, clozapine is the only medication
reported in the literature to have a specific beneficial effect
on patients’ insight in addition to symptoms; thus far,76
however other drugs have not been the focus of such stud-
ies. Greater insight in schizophrenia has been found by
a few studies to be related to strong social support net-
work,77 and interventions such as vocational rehabilita-
tion40 and cognitive behavioral therapy78 have shown
some promise in increasing insight. Further intervention
research related to insight and attitudes is needed.
Limitations
Several methodological limitations require comment.
First, although we used a large longitudinal dataset,
the findings remain associational in nature. Themost per-
suasive set of analyses are the baseline-to-follow-up pre-
dictive models and the change-and-change models, but in
the absence of an experimental design, we cannot con-
clude that insight and positive medication attitudes cause
the benefits in symptoms and QOL. As noted earlier, al-
ternative explanations for these associations such as re-
verse causality and bidirectionality are also plausible.

































































































































































































































































































































































































































































































































































































































































































































































































may lead to reduced symptoms and improved QOL but
also reduction in symptoms attributable to medication
effects may contribute to improved insight andmore pos-
itive medication attitudes.
As noted previously, because we cannot randomly
assign patients to varying levels of insight or attitudes
toward medication, we must rely on associational data
that are invariably less conclusive.
A second limitation of this study is that at many CAT-
IE sites, the rater who administered the ITAQ and the
DAI also completed the PANSS and the HQOL thus in-
troducing a potential rater’s bias. The results, neverthe-
less, point to the importance of exploring patients’
attitudes toward their illness and prescribed medication
as important factors that play an important role in the
recovery process of schizophrenia. The association be-
tween increased insight and decreased in symptoms
and better functioning on one hand and increased depres-
sion on the other fits with the consumer-oriented ap-
proach to recovery, which emphasizes a nonlinear
process of recovery in which the consumer adapts to
and moves beyond the illness on a journey with ‘‘bumps
along the way.’’79 Similarly, Hogan80 in a report on the
New FreedomCommission described recovery ‘‘as a pro-
cess of positive adaptation to illness and disability, linked
strongly to self-awareness and a sense of empowerment.’’
While increase in depression may reflect the emergence of
a discrepancy between an individual’s current function-
ing and their desired functioning, the emergence of dys-
phoria due to awareness of this discrepancy could also
serve to motivate individuals to reduce this discrepancy.
This conceptualization follows the motivational inter-
viewing paradigm81 that emphasizes setting and pursuing
personal goals, which could in the long run lower depres-
sion while preserving insight.
Finally, it should be noted that our measure of medi-
cation compliance was a global assessment by the treating
psychiatrist and was not based on more objective meas-
ures of adherence such as blood level monitoring or mi-
croelectronic monitoring systems that record the specific
time and date whenever the pill bottle is opened.82
Conclusion
This study found that greater patient insight into their
illness and more positive attitudes toward medication
were associated with improved symptom and QOL out-
comes and with greater medication adherence. Interven-
tions developed to improve these attitudes may form an
important part of psychosocial rehabilitation and/or
recovery-oriented service delivery.
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